Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Sterile Injectable Manufacturing: SOP for Handling Deviations in Manufacturing Stages – V 2.0

Posted on By

Sterile Injectable Manufacturing: SOP for Handling Deviations in Manufacturing Stages – V 2.0

Standard Operating Procedure for Handling Deviations in Manufacturing Stages


Department Sterile Injectable Manufacturing
SOP No. SOP/SIM/040/2025
Supersedes SOP/SIM/040/2022
Page No. Page 1 of 14
Issue Date 18/06/2025
Effective Date 20/06/2025
Review Date 18/06/2026

1. Purpose

To establish a systematic procedure for identifying, documenting, evaluating, and resolving deviations from established protocols during any stage of sterile injectable manufacturing. This ensures compliance with GMP standards, continuous improvement, and product quality.

2. Scope

This SOP applies

to all stages of sterile injectable manufacturing where deviations from standard operating procedures, batch records, process parameters, equipment settings, or specifications may occur.

3. Responsibilities

  • Manufacturing Personnel: Immediately identify and report any deviation to the supervisor and initiate documentation.
  • Quality Assurance (QA): Evaluate deviation reports, conduct investigations, determine impact, and approve corrective/preventive actions (CAPA).
  • Department Head: Approves deviation reports and ensures timely closure and implementation of CAPA.
See also  Sterile Injectable Manufacturing: SOP for Review of Batch Manufacturing Records - V 2.0

4. Accountability

The Head of Quality Assurance is accountable for ensuring all deviations are addressed in a timely and compliant manner and that appropriate root cause analysis and CAPA are conducted and documented.

5. Procedure

5.1 Identification of Deviation

  1. A deviation is defined as any departure from approved procedures, standards, or specifications during manufacturing.
  2. Deviations may include: process interruptions, equipment failure, mislabeling, environmental excursions, incorrect component use, or yield variations.
  3. Personnel must immediately inform the Supervisor/QA and record the incident in the Deviation Log Book (Annexure-1).

5.2 Classification of Deviations

  1. Minor Deviation: Non-critical impact, such as documentation error, not affecting product quality or compliance.
  2. Major Deviation: Potential impact on product quality, safety, efficacy, or regulatory compliance.
  3. Critical Deviation: Direct impact on product release, patient safety, or regulatory violation.

5.3 Deviation Documentation

  1. Use the Deviation Report Form (Annexure-2) to record full details, including:
    • Nature of deviation
    • Date and time
    • Equipment/area involved
    • Initial observations
    • Personnel involved
  2. Attach any supporting data, including batch records, logs, and instrument readings.

5.4 Investigation and Impact Assessment

  1. QA initiates investigation within 24 hours of deviation identification.
  2. Evaluate batch impact, including possible effect on:
    • Product quality
    • Process integrity
    • GMP compliance
  3. Conduct root cause analysis using appropriate tools (e.g., Fishbone diagram, 5 Whys).
See also  Sterile Injectable Manufacturing: SOP for Handling Temperature-Sensitive Injectable Formulations - V 2.0

5.5 Corrective and Preventive Action (CAPA)

  1. Define immediate corrective action to contain the deviation.
  2. Design preventive measures to avoid recurrence.
  3. Record CAPA details and implementation responsibility in the Deviation Report Form.
  4. QA must review effectiveness of CAPA post-implementation.

5.6 Approval and Closure

  1. Deviation Report must be reviewed and signed by QA, Manufacturing Head, and approved by Head QA.
  2. All deviations shall be closed within 30 calendar days from date of initiation.
  3. Maintain all Deviation Reports in QA archive for at least 5 years.

6. Abbreviations

  • SOP: Standard Operating Procedure
  • QA: Quality Assurance
  • CAPA: Corrective and Preventive Action
  • GMP: Good Manufacturing Practices

7. Documents

  1. Deviation Log Book – Annexure-1
  2. Deviation Report Form – Annexure-2
  3. CAPA Implementation Checklist – Annexure-3

8. References

  • 21 CFR Part 211.192 – Production Record Review
  • ICH Q10 – Pharmaceutical Quality System
  • EU GMP Volume 4 – Chapter 1 and 8
See also  Sterile Injectable Manufacturing: SOP for Batch Release of Injectable Products - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation Manufacturing Executive QA Executive Head QA
Department Production Quality Assurance Quality Assurance

11. Annexures

Annexure-1: Deviation Log Book

Sr. No. Date Batch No. Deviation Type Initials
001 16/06/2025 IM-3025 Major SK

Annexure-2: Deviation Report Form

Deviation No. DEV-056
Batch No. IV-1005
Date & Time 16/06/2025 – 02:45 PM
Description Observed filling speed deviation beyond defined range
Impact Assessment No impact on fill volume or sterility
Root Cause Improper PID setting
CAPA Technician retrained; parameter settings reviewed

Annexure-3: CAPA Implementation Checklist

CAPA No. Action Responsible Due Date Status
CAPA-103 Recalibrate filler Ajay Deshmukh 20/06/2025 Completed

Revision History

Revision Date Revision No. Details Reason Approved By
05/04/2022 1.0 Initial Release New SOP QA Head
18/06/2025 2.0 Added deviation types, annexures, CAPA checklist Periodic Review QA Head
Injectables V 2.0 Tags:Aseptic processing SOP, Aseptic technique in sterile manufacturing, Cleanroom SOP for injectables, SOP for ampoule sealing, SOP for autoclave sterilization, SOP for container closure integrity testing, SOP for environmental monitoring in aseptic area, SOP for gowning in cleanroom, SOP for in-process checks in sterile manufacturing, SOP for injectable formulation, SOP for lyophilizer operation, SOP for sterile filtration, SOP for sterilization validation, SOP for vial filling, SOP for visual inspection of injectables, Sterile area cleaning SOP, Sterile filling line SOP, Sterile injectable quality control SOP, Sterile injection SOP, Sterile manufacturing procedure

Post navigation

Previous Post: BA-BE Studies: SOP for Reproducibility Assessment Across Runs – V 2.0
Next Post: Analytical Method Development: Laser Diffraction Method Optimization – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version